Barclays Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $140
Merck & Co Analyst Ratings
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $130
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $130
Wells Fargo Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $125
Wells Fargo Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $125
Merck & Co Analyst Ratings
Truist Financial Maintains Merck & Co(MRK.US) With Buy Rating, Announces Target Price $132
UBS Maintains Merck & Co(MRK.US) With Buy Rating, Raises Target Price to $136
Truist Financial Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $132
TD Cowen Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $140
Merck Price Target Cut to $140.00/Share From $142.00 by Barclays
Merck & Co Analyst Ratings
Barclays Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $140
Merck & Co Analyst Ratings
Gritstone Downgraded by Jones, B. Riley Over Cancer Vaccine Data
Barclays Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $142
Barclays Reaffirms Their Buy Rating on Merck & Company (MRK)
J.P. Morgan Maintains Merck & Co(MRK.US) With Buy Rating, Announces Target Price $145
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $130